Background
Maint text
Biology of immune inhibitory molecules
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
Programmed death-1 (PD-1)
Lymphocyte activation gene-3 (LAG-3)
T cell immunoglobulin and mucin domain-containing protein-3 (TIM-3)
Aberrancies in immune checkpoint molecules in hematological malignancies
Lymphomas
Plasma cell myeloma (PCM)
Myeloid neoplasms
Role of checkpoint inhibition in hematological malignancies
Lymphomas
Malignancies | Clinical trial # | Phase | Drug | Study description | Other name |
---|---|---|---|---|---|
Lymphoid neoplasm | NCT02181738 | 2 | Nivolumab | Clinical activity of anti-PD-1 antibody in R/R CHL patients | CheckMate 205 |
NCT01953692 | 2 | Pembrolizumab | Clinical activity of anti-PD-1 antibody in R/R CHL patients | KEYNOTE-013 | |
NCT02857426 | 2 | Nivolumab | Anti-PD-1 antibody in R/R PCNSL and PTL | ||
NCT02576990 | 2 | Pembrolizumab | Anti-PD-1 antibody in R/R PMBL | KEYNOTE-170 | |
NCT02220842 | 1 | Atezolizumab | Anti-PD-L1 antibody in combination with anti-CD20 antibody to R/R DLBCL or FL | ||
Plasma cell neoplasm | NCT02036502 | 1 | Pembrolizumab | Clinical activity of anti-PD-1, lenalidomide and low-dose dexamethasone in R/R PCM patients shown | KEYNOTE-023 |
NCT02903381 | 2 | Nivolumab | Lenalidomide, low-dose dexamethasone and anti-PD-1 antibody in smoldering PCM patients | ||
NCT01592370 | 1 | Nivolumab | Clinical activity of anti-PD-1 antibody in R/R PCM patients | ||
NCT02726581 | 3 | Nivolumab | Pomalidomide and dexamethasone with or without anti-PD-1 antibody in R/R PCM patients | CheckMate 602 | |
NCT02579863 | 3 | Pembrolizumab | Pomalidomide and dexamethasone with or without anti-PD-1 antibody in treatment-naïve PCM patients | KEYNOTE-185 | |
Myeloid neoplasms | NCT02530463 | 2 | Nivolumab | HMA, ipilimumab, and anti-PD-1 antibody in MDS patients | |
NCT01953692 | 1 | Pembrolizumab | Anti-PD-1 antibody in HMA-failed MDS patients | ||
NCT02845297 | 2 | Pembrolizumab | Anti-PD-1 with HMA in R/R AML patients | ||
NCT02275533 | 2 | Nivolumab | Anti-PD-1 antibody as post-remission therapy in AML patients | ||
NCT02117219 | 1 | Durvalumab | Anti-PD-L1 antibody, HMA, and tremelimumab in MDS patients |
Plasma cell myeloma
Myeloid neoplasms
Side effects of checkpoint therapy
Biomarkers related to checkpoint inhibitor therapy
Technology | Target cells/tissue | Purpose | Reference |
---|---|---|---|
Immunohistochemistry | FFPE tissue | Analysis of protein expression in tumor cells Immune cell profiling in TME | |
Flow cytometry | Blood, fresh/frozen tumor tissue | Analysis of different subsets of immune cells | [141] |
ELISA | Blood | Analysis of cytokine Chemokine and antibodies against tumor-specific antigen | [162] |
Enzyme-linked immunospot | Blood | Quantification of T or B cells, Analysis of cytokine and chemokine | [158] |
Protein microarray | Blood | Analysis of antibody signature | [159] |
Gene expression profiling | Blood, fresh/frozen/FFPE tumor tissue | Analysis of gene signatures in tumor/immune cells | [145] |
TCR deep sequencing | Blood | T cell receptor profiling | [160] |
NGS (WES, RNA-seq) | Fresh/FFPE tissue | Mutational load Prediction of immunogenecity of tumor neoantigens | |
Epigenomics | Blood, fresh/frozen/FFPE tumor tissue | Analysis of immune cell specific epigenetic changes | [161] |